NCT06205134 - Comparative Bioavailability of Intranasal Epinephrine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

February 5, 2024

Conditions

AnaphylaxisAnaphylactic Reaction

Interventions

DRUG

A: Epinephrine injection

Autoinjector for intramuscular, single-use, 0.3mg

DRUG

B: FMXIN002 3.6mg

Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril

DRUG

C: FMXIN002 4.0mg

Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril

Trial Locations (1)

Clinical Pharmacology Unit, Hadassah Medical Center, Ein Karem, Jerusalem